Idarucizumab for Dabigatran Reversal

20151,445 citationsJournal Article

Authors

Charles V. Pollack · University of Pennsylvania

Paul A. Reilly · Boehringer Ingelheim (Germany)

John W. Eikelboom · McMaster University

Stephan Glund · Boehringer Ingelheim (Taiwan)

Peter Verhamme · KU Leuven

G. M. Bernstein · Northwestern University

Robert Dubiel ·

Abstract

Idarucizumab completely reversed the anticoagulant effect of dabigatran within minutes. (Funded by Boehringer Ingelheim; RE-VERSE AD ClinicalTrials.gov number, NCT02104947.).

Topics & Keywords

Atrial Fibrillation Management and Outcomes Venous Thromboembolism Diagnosis and Management Heparin-Induced Thrombocytopenia and Thrombosis

Publication Details

Published in: New England Journal of Medicine

Volume 373, Issue 6, pp. 511-520

DOI: 10.1056/nejmoa1502000

Field-Weighted Citation Impact: 204.60

Command Palette

Idarucizumab for Dabigatran Reversal

Authors

Abstract

Topics & Keywords

Publication Details